The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kalinin P.L.

NII neĭrokhirurgii im. N.N. Burdenko RAMN, Moskva

Astaf'eva L.I.

NII neĭrokhirurgii im. N.N. Burdenko RAMN, Moskva

Kadashev B.A.

NII neĭrokhirurgii im. N.N. Burdenko RAMN, Moskva

Ismailov D.B.

Burdenko Neurosurgical Institute, Moscow, Russia

Indications for surgical treatment of prolactin-secreting pituitary adenomas

Authors:

Kalinin P.L., Astaf'eva L.I., Kadashev B.A., Ismailov D.B.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2017;81(5): 117‑124

DOI: 10.17116/neiro2017815117-124

Read: 13212 times

Contact the author
Table of contents

INDICATIONS FOR SURGICAL TREATMENT OF PROLACTIN-SECRETING PITUITARY ADENOMAS
INDICATIONS FOR SURGICAL TREATMENT OF PROLACTIN-SECRETING PITUITARY ADENOMAS

To cite this article:

Kalinin PL, Astaf'eva LI, Kadashev BA, Ismailov DB. Indications for surgical treatment of prolactin-secreting pituitary adenomas. Burdenko's Journal of Neurosurgery. 2017;81(5):117‑124. (In Russ., In Engl.)
https://doi.org/10.17116/neiro2017815117-124

Подписка 2025 Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко (Burdenko's Journal of Neurosurgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Lost anatomical stru­cture — pharyngeal pituitary gland (Hypophysis pharyngealis or Erdheim pituitary gland): a review and case report. Burdenko's Journal of Neurosurgery. 2026;(1):83-91
First clinical application of auto­logous fibrin sealant Vivo­stat for neurosurgery in Kaza­khstan and Central Asia. Burdenko's Journal of Neurosurgery. 2026;(2):70-76
Impact of cabe­rgoline on fibrosis in prolactinoma. Burdenko's Journal of Neurosurgery. 2026;(2):85-91
Genome instability of the cholera agent: role in the evolution of pathogenicity, drug resi­stance and adaptation to a changing envi­ronment. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(2):3-13
Primary multiple hype­rtensive intracerebral hemo­rrhages. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):98-102
Abstract:

Prolactinomas account for about 40% of all pituitary adenomas. The main treatment for prolactinomas is undoubtedly therapy with dopamine agonists (DAs). However, prolonged conservative treatment (for many years or even throughout life) that is necessary for permanent control of the disease makes some patients refuse pharmacological treatment for various reasons. In addition, not all prolactinomas respond to DAs therapy. Sometimes, the patient is not able to continue treatment because of the severity of side effects. Along with tumor resistance to therapy and patient intolerance of DAs, complications (liquorrhea, hemorrhage in the tumor) may occur during conservative treatment. In these cases, surgery is necessary. The paper analyzes the modern literature on various treatment options for prolactin-secreting pituitary adenomas and defines the indications for surgical treatment.

Keywords:

prolactinomas
prolactin-secreting pituitary adenomas
pituitary adenomas
transsphenoidal surgery
hyperprolactinemia
dopamine agonists
cabergoline
bromocriptine
liquorrhea
resistance
hemorrhage

Authors:

Kalinin P.L.

NII neĭrokhirurgii im. N.N. Burdenko RAMN, Moskva

Astaf'eva L.I.

NII neĭrokhirurgii im. N.N. Burdenko RAMN, Moskva

Kadashev B.A.

NII neĭrokhirurgii im. N.N. Burdenko RAMN, Moskva

Ismailov D.B.

Burdenko Neurosurgical Institute, Moscow, Russia

Close metadata

References:

  1. Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary. 2005;8(1):3-6. https://doi.org/10.1007/s11102-005-5079-0
  2. Daly AF, Tichomirowa MA, Beckers A. The epidemiology and genetics of pituitary adenomas. Best practice & research Clinical endocrinology & metabolism. 2009;23(5):543-554. https://doi.org/10.1016/j.beem.2009.05.008
  3. Kadashev BA. Pituitary adenomas: clinicaly, diagnostics, treatment. Tver’: Triada. 2007;368. (In Russ.)
  4. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clinical endocrinology. 2010;72(3):377-382. https://doi.org/10.1111/j.1365-2265.2009.03667.x
  5. Oh MC, Kunwar S, Blevins L, Aghi MK. Medical versus surgical management of prolactinomas. Neurosurgery clinics of North America. 2012;23(4):669-678. https://doi.org/10.1016/j.nec.2012.06.010
  6. Halperin Rabinovich I, Camara Gomez R, Garcia Mouriz M, Ollero Garcia-Agullo D. Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia. Endocrinologia y nutricion: organo de la Sociedad Espanola de Endocrinologia y Nutricion. 2013;60(6):308-319. https://doi.org/10.1016/j.endonu.2012.11.005
  7. Kalinin PL. Endoscopic transsphenoidal surgery of pituitary adenomas and other tumors parasellar localization: Dis... d-ra med. nauk. M. 2009. (In Russ.)
  8. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. The Journal of clinical endocrinology and metabolism. 2011;96(2):273-288. https://doi.org/10.1210/jc.2010-1692
  9. Astaf’eva LI. Clinical and morphological features and results of medicamentous and surgical treatment of prolactin-secreting pituitary macroadenoma: Dis... d-ra med. nauk. M 2012. (In Russ.)
  10. Biller BM, Colao A, Petersenn S, Bonert VS, Boscaro M. Prolactinomas, Cushing’s disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC endocrine disorders. 2010;10:10. https://doi.org/10.1186/1472-6823-10-10
  11. Landolt AM, Osterwalder V, Landolt TA. Bromocriptine-induced removal of endoplasmic membranes from prolactinoma cells. Experientia. 1985;41(5):640-642.
  12. Tindall GT, Kovacs K, Horvath E, Thorner MO. Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. The Journal of clinical endocrinology and metabolism. 1982;55(6):1178-1183. https://doi.org/10.1210/jcem-55-6-1178
  13. Warfield A, Finkel DM, Schatz NJ, Savino PJ, Snyder PJ. Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function. Annals of internal medicine. 1984;101(6):783-785.
  14. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. The Journal of clinical endocrinology and metabolism. 1985;60(4):698-705. https://doi.org/10.1210/jcem-60-4-698
  15. Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrilli S, Lombardi G. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. The Journal of clinical endocrinology and metabolism. 2004;89(4):1704-1711. https://doi.org/10.1210/jc.2003-030979
  16. Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary. 2005;8(1):43-52. https://doi.org/10.1007/s11102-005-5085-2
  17. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. The New England journal of medicine. 1994;331(14):904-909. https://doi.org/10.1056/nejm199410063311403
  18. Pascal-Vigneron V, Weryha G, Bosc M, Leclere J. Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse medicale (Paris, France, 1983). 1995;24(16):753-757.
  19. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. The Journal of clinical endocrinology and metabolism. 2008;93(12):4721-4727. https://doi.org/10.1210/jc.2007-2758
  20. Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clinical endocrinology. 2005;63(1):26-31. https://doi.org/10.1111/j.1365-2265.2005.02293.x
  21. Cannavo S, Curto L, Squadrito S, Almoto B, Vieni A, Trimarchi F. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. Journal of endocrinological investigation. 1999;22(5):354-359. https://doi.org/10.1007/bf03343573
  22. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. The New England journal of medicine. 2003;349(21):2023-2033. https://doi.org/10.1056/NEJMoa022657
  23. Kharlip J, Salvatori R, Yenokyan G, Wand GS. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. The Journal of clinical endocrinology and metabolism. 2009;94(7):2428-2436. https://doi.org/10.1210/jc.2008-2103
  24. Molitch ME. Medical treatment of prolactinomas. Endocrinology and metabolism clinics of North America. 1999;28(1):143-169;7.
  25. Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. Journal of endocrinological investigation. 1997;20(9):537-546. https://doi.org/10.1007/bf03348016
  26. Sinha S, Sharma BS, Mahapatra AK. Microsurgical management of prolactinomas — clinical and hormonal outcome in a series of 172 cases. Neurology India. 2011;59(4):532-536. https://doi.org/10.4103/0028-3886.84332
  27. Gnjidic Z, Kudelic N, Sajko T, Malenica M, Stipic D, Rotim K. Surgical treatment of prolactinomas—our experience. Collegium antropologicum. 2014;38(2):571-576.
  28. Bloomgarden E, Molitch ME. Surgical treatment of prolactinomas: cons. Endocrine. 2014;47(3):730-733. https://doi.org/10.1007/s12020-014-0369-9
  29. Babey M, Sahli R, Vajtai I, Andres RH, Seiler RW. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists. Pituitary. 2011;14(3):222-230. https://doi.org/10.1007/s11102-010-0283-y
  30. Wong A, Eloy JA, Couldwell WT, Liu JK. Update on prolactinomas. Part 2: Treatment and management strategies. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia. 2015;22(10):1568-1574. https://doi.org/10.1016/j.jocn.2015.03.059
  31. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A. Resistance to bromocriptine in prolactinomas. The Journal of clinical endocrinology and metabolism. 1989;69(3):500-509. https://doi.org/10.1210/jcem-69-3-500
  32. Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. The Journal of clinical endocrinology and metabolism. 2001;86(11):5256-5261. https://doi.org/10.1210/jcem.86.11.8054
  33. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. The New England journal of medicine. 2007;356(1):39-46. https://doi.org/10.1056/NEJMoa054830
  34. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. The New England journal of medicine. 2007;356(1):29-38. https://doi.org/10.1056/NEJMoa062222
  35. Molitch ME. Management of medically refractory prolactinoma. Journal of neuro-oncology. 2014;117(3):421-428. https://doi.org/10.1007/s11060-013-1270-8
  36. Delgrange E, Crabbe J, Donckier J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Hormone research. 1998;49(5):250-253.
  37. McCall D, Hunter SJ, Cooke RS, Herron B, Sheridan B, Atkinson AB. Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma. Clinical endocrinology. 2007;66(1):149-150. https://doi.org/10.1111/j.1365-2265.2006.02686.x
  38. Astaf’eva LI, Kadashev BA, Trunin YuYu, Rotin DL. The development of «secondary» resistant to dopamine agonists in a patient with giant prolactinoma. Voprosy neirokhirurgii. 2010;4:48-52. (In Russ.)
  39. Kissner DG, Jarrett JC. Side effects of bromocriptine. The New England journal of medicine. 1980;302(13):749-750. https://doi.org/10.1056/nejm198003273021313
  40. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug safety. 1996;14(4):228-238.
  41. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocrine reviews. 2006;27(5):485-534. https://doi.org/10.1210/er.2005-9998
  42. Smith TR, Hulou MM, Huang KT, Gokoglu A, Cote DJ, Woodmansee WW, Laws ERJr. Current indications for the surgical treatment of prolactinomas. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia. 2015;22(11):1785-1791. https://doi.org/10.1016/j.jocn.2015.06.001
  43. Astaf’eva LI, Kadashev BA, Dedov II, Kalinin PL, Kutin MA, Shkarubo AN, Fomichev DV, Tenedieva VD, Tropinskaya OF. A comparative study of results of surgical and medicamentous methods of treatment macroprolactinoma various locations. Voprosy neirokhirurgii. 2011;75(4):3-9. (In Russ.)
  44. Akin S, Isikay I, Soylemezoglu F, Yucel T, Gurlek A, Berker M. Reasons and results of endoscopic surgery for prolactinomas: 142 surgical cases. Acta neurochirurgica. 2016;158(5):933-942. https://doi.org/10.1007/s00701-016-2762-z
  45. Primeau V, Raftopoulos C, Maiter D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. European journal of endocrinology. 2012;166(5):779-786. https://doi.org/10.1530/EJE-11-1000
  46. Qu X, Wang M, Wang G, Han T, Mou C, Han L, Jiang M, Qu Y, Zhang M, Pang Q, Xu G. Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases. European journal of endocrinology. 2011;164(4):499-504. https://doi.org/10.1530/eje-10-0961
  47. Sinkunas K, Rastenyte D, Deltuva VP, Knispelis R, Tamasauskas A. Transsphenoidal surgery for prolactinomas: results and prognosis. Medicina (Kaunas, Lithuania). 2007;43(9):691-697.
  48. Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. European journal of endocrinology. 2008;158(1):11-18. https://doi.org/10.1530/eje-07-0248
  49. Salvatori R. Surgical treatment of microprolactinomas. Endocrine. 2014;47(3):725-729. https://doi.org/10.1007/s12020-014-0281-3
  50. Thomson JA, Gray CE, Teasdale GM. Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up. Neurosurgery. 2002;50(1):36-39;discussion 9-40.
  51. Berkmann S, Fandino J, Muller B, Kothbauer KF, Henzen C, Landolt H. Pituitary surgery: experience from a large network in Central Switzerland. Swiss medical weekly. 2012;142:w13680. https://doi.org/10.4414/smw.2012.13680
  52. Loyo-Varela M, Herrada-Pineda T, Revilla-Pacheco F, Manrique-Guzman S. Pituitary tumor surgery: review of 3004 cases. World neurosurgery. 2013;79(2):331-336. https://doi.org/10.1016/j.wneu.2012.06.024
  53. Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J, Trouillas J. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. The Journal of clinical endocrinology and metabolism. 2010;95(4):1708-1716. https://doi.org/10.1210/jc.2009-1191
  54. Tamasauskas A, Sinkunas K, Bunevicius A, Radziunas A, Skiriute D, Deltuva VP. Transsphenoidal surgery for microprolactinomas in women: results and prognosis. Acta neurochirurgica. 2012;154(10):1889-1893. https://doi.org/10.1007/s00701-012-1450-x
  55. Kalinin PL, Fomichev DV, Kutin MA, Kadashev BA, Astaf’eva LI, Shkarubo AN, Alekseev SN, Fomochkina LA. Endoscopic endonasal surgery of pituitary adenomas (experience 1700 operations). Voprosy neirokhirurgii. 2012;76(3):26-33. (In Russ.)
  56. Song YJ, Chen MT, Lian W, Xing B, Yao Y, Feng M, Wang RZ. Surgical treatment for male prolactinoma: A retrospective study of 184 cases. Medicine. 2017;96(2):e5833. https://doi.org/10.1097/md.0000000000005833
  57. Ikeda H, Watanabe K, Tominaga T, Yoshimoto T. Transsphenoidal microsurgical results of female patients with prolactinomas. Clinical neurology and neurosurgery. 2013;115(9):1621-1625. https://doi.org/10.1016/j.clineuro.2013.02.016
  58. Chen MT, Song YJ, Lian W, Xing B, Yao Y, Feng M, Wang RZ. Analysis of curative effect of surgical therapy for male prolactinoma. Zhonghua yi xue za zhi. 2016;96(19):1477-1480. https://doi.org/10.3760/cma.j.issn.0376-2491.2016.19.003
  59. Ogiwara T, Horiuchi T, Nagm A, Goto T, Hongo K. Significance of surgical management for cystic prolactinoma. Pituitary. 2016. https://doi.org/10.1016/j.wneu.2016.10.059
  60. Barker FG2nd, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996—2000: mortality, morbidity, and the effects of hospital and surgeon volume. The Journal of clinical endocrinology and metabolism. 2003;88(10):4709-4719. https://doi.org/10.1210/jc.2003-030461
  61. Astaf’eva LI, Kadashev BA, Kalinin PL, Kutin MA, Faizullaev RB, Sidneva YuG, Tenedieva VD, Tropinskaya OF. The choice of treatment prolactinsecreting giant pituitary adenomas. Voprosy neirokhirurgii. 2009;2:23-28. (In Russ.)
  62. Lam G, Mehta V, Zada G. Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature. Neurosurgical focus. 2012;32(6):E2. https://doi.org/10.3171/2012.4.focus1268
  63. Kok JG, Bartelink AK, Schulte BP, Smals A, Pieters G, Meyer E, Merx H. Cerebrospinal fluid rhinorrhea during treatment with bromocriptine for prolactinoma. Neurology. 1985;35(8):1193-1195.
  64. Afshar F, Thomas A. Bromocriptine-induced cerebrospinal fluid rhinorrhea. Surgical neurology. 1982;18(1):61-63.
  65. Astaf’eva LI, Kadashev BA, Kutin MA, Kalinin PL. Complications of treatment with macroprolactinomas dopamine agonists. Voprosy neirokhirurgii. 2011;2:41-50. (In Russ.)
  66. Brodsky JB, Cohen EN, Brown BWJr, Wu ML, Whitcher C. Surgery during pregnancy and fetal outcome. American journal of obstetrics and gynecology. 1980;138(8):1165-1167.
  67. Imran SA, Ur E, Clarke DB. Managing prolactin-secreting adenomas during pregnancy. Canadian family physician Medecin de famille canadien. 2007;53(4):653-658.
  68. Yan Z, Wang Y, Shou X, Su J, Lang L. Effect of transsphenoidal surgery and standard care on fertility related indicators of patients with prolactinomas during child-bearing period. International journal of clinical and experimental medicine. 2015;8(11):21557-21564.
  69. Jethwa PR, Patel TD, Hajart AF, Eloy JA, Couldwell WT, Liu JK. Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States. World neurosurgery. 2016;87:65-76. https://doi.org/10.1016/j.wneu.2015.10.090
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.